Jazz Pharmaceuticals PLC (JAZZ) saw its stock price plummet 6.16% in Tuesday's trading session following the release of its first-quarter 2025 financial results, which significantly missed analyst expectations across key metrics.
The biopharmaceutical company reported Q1 revenue of $897.841 million, falling short of the IBES estimate of $985.4 million. Adjusted earnings per share (EPS) came in at $1.68, well below the expected $4.66. The company's adjusted net income for the quarter was $105.233 million, considerably lower than the estimated $288.6 million. Jazz Pharmaceuticals also reported a net loss of $92.541 million, translating to a loss per share of $1.52.
In light of these disappointing results, Jazz Pharmaceuticals announced updates to its 2025 financial guidance, though specific details were not immediately available. Investors and analysts will likely be closely monitoring the company's future outlook and potential strategies to improve performance in the coming quarters.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.